5.1
The Committee supported the ongoing research investigating dapagliflozin as part of a triple therapy regimen as add-on to 2 oral antidiabetic drugs.
The Committee supported the ongoing research investigating dapagliflozin as part of a triple therapy regimen as add-on to 2 oral antidiabetic drugs.